The combination of sulphamethoxazole and trimethoprim (Bactrim, Septrin) has been available as a chemotherapeutic agent in general use for about two years. It would therefore seem useful at this stage to review published and personal experience with the combination in an attempt to define its probable future role in antibacterial chemotherapy.
Mode of Action
Sulphonamides are thought to produce their antibacterial effect by competing with the natural precursor p-aminobenzoic acid in the formation of folic acid (Fig. 1) . In man, the folate pathway requires exogenous folate as its initial substrate so the step blocked by sulphonamides is absent, thus forming the basis for their selective toxicity for bacteria. The next step in the folate pathway is the conversion of folic acid to folinic acid by the en- zyme dihydrofolate reductase. Trimethoprim binds strongly to this enzyme in bacteria and blocks this reduction, but binds only weakly to the mammalian enzyme. The presence of blocks at two sequential stages in the folate pathway leads, among other things, to a cessation of DNA synthesis and the death of the bacterium. The sequential nature of the blockage has also been taken to explain the synergistic antibacterial action between sulphonamides and trimethoprim.
The drugs are effective in vivo, where folates and folinates abound, because almost all pathogenic bacterial species are unable to absorb and utilize these compounds from an exogenous source (Bushby and Hitchings, 1968) .
Activity in Vitro
The activity of the individual drugs will be considered first, and then their activity in combination.
TRIMETHOPRIM
The activity of trimethoprim against a number of common pathogens is summarized in Table I from the data of Bushby and Hitchings (1968) ; Darrell, Garrod, and Waterworth (1968) ; and Phillips, Ridley, Rimmer, Lynn, and Warren (1970 Figure 2 shows data taken from a paper by Brumfitt and Percival (1967) and illustrates this point well. Although the minimal inhibitory concentrations (MIC) shown were estimated using sulphadimidine, it is generally agreed that the sensitivities of bacteria to different sulphonamides are usually in fair agreement. The results in Fig. 2 The sensitivity of various bacterial pathogens to sulphonamides varies widely but sensitive strains have MICs of < 50 ,ug/ml. Infections with organisms having an MIC above this figure are less likely to be eradicated by sulphonamide therapy (Williams and Leigh, 1966) , and treatment is particularly likely to fail if the MIC is > 200 ,ug/ml.
COMBINED ACTIVITY
The difficulty in reviewing the action of the sulphamethoxazole/trimethoprim combination is that not only has the activity of the individual components to be described but that additive or synergistic effects, ie, potentiation, between the two drugs must also be considered.
Synergism
That synergism between these two drugs occurs has 431 been shown by Bushby and Hitchings (1968) and Darrell et al (1968) , some of the information being summarized in Table II potentiation which occurs depends on the ratio of the concentrations of sulphamethoxazole and trimethoprim used, and tends to be maximal when the drug ratio of the concentrations is similar to that of their respective MICs (Bushby and Hitchings, 1968) . Thus, for a range of organisms sensitive to both drugs the ratio would be about 20 parts of sulphamethoxazole (MICs 5-50 ,ug/ml) to one part of trimethoprim (MICs 0 25-2 ,g/ml), although it may vary widely with individual species. Neisseria gonorrhoeae is an exception in which the ratios of the MICs of sulphamethoxazole and trimethoprim are completely reversed, the organism sometimes being more sensitive to sulphonamides than to trimethoprim. Evidence of synergistic activity has also been found in vivo in experimental infections in mice (Bushby and Hitchings, 1968; Bohni, 1969) and in the treatment of gonorrhoeae (Table III) produces a cure rate of only about 30% because of the prevalence of acquired sulphonamide resistance. Combined therapy gives a high cure rate similar to that produced by penicillin G. This effect seems to be greater than that produced by simple addition of activities and must surely represent true synergy.
Addition
Apart from the occurrence of synergy another reason for the administration of a sulphonamide with trimethoprim is that the additive action of the two drugs makes the administration of a lower dose of both drugs possible, thus reducing the incidence of side effects.
Two further reasons for combined administration are the prevention of acquisition of resistance to trimethoprim, and the conversion of the bacteriostatic activity of both drugs to a bactericidal action.
Prevention of resistance Bacteria can be 'trained' to trimethoprim resistance by serial subculture on trimethoprim-containing medium (Darrell et al, 1968) . The development of this resistance is reduced by the addition of sulphonamide to the medium, the effect being less noticeable when the organism used is resistant to sulphonamides.
Bactericidal activity
The sulphonamides are well known to be bacteriostatic, and trimethoprim is similar in this respect. When both drugs are used in combination, however, they may be bactericidal (Bushby, 1969a) . How often this effect occurs with individual species or strains is not known, but it probably occurs often enough to make it yet another indication for combining trimethoprim with sulphonamide rather than using it alone.
Antagonism between sulphonamides and trimethoprim has not been demonstrated (Bushby, 1969b) , nor between trimethoprim and other antibiotics.
Pharmacology

ADMINISTRATION
The drugs are presented in tablets (Septrin') or drapsules (Bactrim') containing 400 mg of sulphamethoxazole and 80 mg of trimethoprim, ie, a sulphonamide/trimethoprim ratio of 5:1. This ratio of administration is used because it was found by experience that it produced a ratio in the blood of 20: 1 (see Fig. 3 , for example) and, as mentioned above, this is most likely to give maximal potentiation for a wide variety of organism.
,UK only ABSORPTION The uptake of both sulphamethoxazole and trimethoprim from the intestinal tract following oral administration is rapid and good blood levels are obtained. The results of giving Septrin to four fasting volunteers ( Fig. 3 ) illustrates this and also shows that there is remarkably little deviation from the mean values produced. More important, uptake of both drugs in patients under treatment is also satisfactory (Fig. 4) . Some accumulates after the initial dose, the mean levels being higher with repeated administration. Both drugs are excreted by the kidneys, trimethoprim largely in an unchanged form, producing high urinary levels (see Brumfitt, Faiers, Pursell, Reeves, and Turnbull, 1969) . As would be expected, blood levels of both drugs are higher in patients with renal failure. . Of the other sulphonamides available, sulphadimidine is excreted best in prostatic fluid (Winningham and Stamey, 1970) , and a combination of this drug with trimethoprim may therefore be better for treating prostatic infection, although MICs to sulphadimidine are in general higher than to sulphamethoxazole.
In spite of these criticisms of the fixed ratio, the marketing of a number of preparations with different ratios would produce complexities beyond the comprehension of many prescribers and could lead to serious therapeutic errors. All that can be said at present is that for serious and difficult infections in (Williams, Brumfitt, Condie, and Reeves, 1969) , even in those patients in whom treatment with another agent had already failed. In view of the fact that pregnancy pyelonephritis is as common in women in whom treatment for bacteriuria has failed as in untreated women (Williams, Brumfitt, Condie, and Reeves, 1969) , confirmation of our findings would seem to represent an advance in therapy. Unfortunately, because of teratogenicity in animals given high doses of trimethoprim (Udall, 1969) , its use in pregnancy is not recommended and such confirmation is unlikely to be forthcoming in the near future. In the relatively small number of women we treated, all after the 12th week of pregnancy, no congenital malformations attributable to the drug were found in a careful follow-up study.
As mentioned previously, sulphonamide resistance is common among urinary pathogens isolated from hospital patients (Fig. 2) and, hardly surprisingly, the cure rate with sulphonamide therapy allocated on a random basis as treatment for urinary infection is low (Table VII, Reeves, Faiers, Pursell, and Brumfitt, 1969 suggested that the chances of successful treatment of a urinary infection with the combination increased with increasing in vitro potentiation of sulphamethoxazole by trimethoprim, although a statistical significance was not reached. Successful results have also been claimed in respiratory infections, including the prevention and treatment of the exacerbations of chronic bronchitis and the treatment of pneumonia. A disturbing aspect of respiratory infections has been the description of the isolation of Haemophilus influenzae highly resistant to trimethoprim from patients on longterm treatment with the combination (Waterworth, 1969) . In view of the possible importance of sulphonamide in preventing the emergence of resistance to trimethoprim, the relatively low sputum levels of sulphamethoxazole (Table IV) may be relevant. Furthermore, May (1969) has described the early relapse of infection in patients treated for chronic bronchitis and suggested that the therapy appears to be bacteriostatic in nature. The levels of sulphamethoxazole in sputum may again be relevant. In fairness it must be mentioned, however, that other workers have clearly demonstrated eradication of pathogens from thesputum (Hughes, 1969) andacomparatively low early recurrence rate (Pines, 1970) .
The use of sulphamethoxazole/trimethoprim for the treatment of gonorrhoea has definite attractions. In addition to producing a high cure rate, the combination has no activity against the spirochaetes causing syphilis and there is therefore no chance of masking a concomitant syphilitic infection. A disadvantage is that at least four days' treatment must be taken if conventional doses are employed.
Two other particular reports are of interest. One is the use of the combination in ulcerative colitis, where the effect produced might be associated with the recently described immunosuppressive activity of trimethoprim (Ghilchik, Morris, and Reeves, 1970) . The other is a report of successful use in the prevention of infection in leucopenic patients (Grineberg, Emmerson, Prankerd, and Souhamie, 1970) . Although some bacteria commonly causing opportunistic infections are 'resistant' to sulphamethoxazole/trimethoprim, it should be remembered that the combination is only required to prevent establishment of infection from a small, initiating inoculum whereas sensitivity or resistance is usually judged on the basis of what is needed for treating the large number oforganisms in established infection.
Toxicity
The toxicity of sulphamethoxazole/trimethoprim can be that of the individual components of the combination and perhaps also the result of both drugs acting to produce a single effect. Although much of the recent literature concentrates on the mechanism of the toxic potential of trimethoprim (e.g. Kahn, Fein, and Brodsky, 1968) , it must be remembered that large amounts of sulphamethoxazole are being administered in the combination, and sulphonamide side effects will also occur. Minor side effects (skin rash, nausea, vomiting, glossitis) occur occasionally after giving the combination Williams et al, 1969) . On the evidence available, serious haematological side effects have only occurred very rarely during the administration of what is conservatively estimated to be 40,000,000 tablets of the combination so far. Thrombocytopenia seems to be the most common serious blood defect (Handley, 1969) , but as both this and neutropenia are found in ill patients, particularly those with virus infections, the significance of their presence after drug administration is hard to assess. There seems to be a particular association between thrombocytopenia and heart failure (Palva, Salokannel, and Takkunen, 1970) . The administration of the combination to patients with heart failure might be better avoided, especially if a thiazide drug is also being given. It has also been suggested that neutropenia is particularly likely to occur when the combination is given to patients within 60 days of receiving a homotransplanted kidney (Hulme and Reeves, unpublished data).
Laboratory Control DISC SENSITIVITY TESTING
The practical aspects of this topic have already been discussed by Waterworth (1969) . The importance of the correct choice of medium and control of inoculum size should be emphasized. It would appear that Oxoid DST agar containing lysed horse blood is a generally suitable medium. Very heavy inocula should be avoided since they selectively reduce inhibition zones to sulphonamides.
A more controversial problem is the choice of suitable discs since bacteria can be tested either against each drug separately or both together in a combined disc. The former method gives the most information about the activity of the individual drugs against the bacteria but significant and useful degrees of synergy may well be missed. Although synergy cannot be conclusively demonstrated by the use of a combined disc alone, its effect (and hence its therapeutic potential), if present at the ratio of the two drugs employed, is more likely to be detected. There is no doubt that ideally both methods should be employed and this can be recommended for serious or difficult infections. It is, however, time consuming and extravagant in materials and, for simple infections (for example a lower urinary tract infection) a combined disc test determining overall sensitivity to the combination is probably sufficient.
Further argument on this point is fruitless at present since more work is needed, for example, in assessing the importance of initial resistance to sulphonamide in determining the development of resistance to trimethoprim during therapy, or the occurrence of potentiation when the organism is partially or fully resistant to one or both drugs. Until points like these are resolved by carefully conducted clinico-microbiological studies the formulation of sensitivity testing procedures cannot usefully be finalized.
DETERMINATION OF MINIMAL INHIBITORY CONCENTRATION
For both sulphonamide and trimethoprim an agar dilution technique with multiple loop inoculation (Darrell et al, 1968) can be used. Careful control of the inoculum size is essential for reproducible results andwe use an inoculum concentration of only 10%-104 organisms/ml to ensure meaningful sulphonamide minimum inhibitory concentrations.
SERUM LEVELS OF DRUGS
The estimation of sulphonamide in body fluids can be rapidly and simply done by a chemical method (Bratton and Marshall, 1939 , as described and modified by Varley, 1967) . Trimethoprim can be estimated by a rather complex microbiological method fully described by Reeves and Ghilchik (1970) . Although a simpler method, more suitable for clinical use, has been described (Pechere, 1970) it still requires a full evaluation by comparison with standard methods. A spectrofluorimetric method has also been described (Schwartz, Koechlin, and Weinfeld, 1969) 
Prospect
The resuts of laboratory and clinical studies to date have shown sulphamethoxazole/trimethoprim in combination to be a chemotherapeutic agent of wide application. Its place in the chemotherapeutic armamentarium of the future will depend on three main factors considered in relationship to other drugs available: (1) the ease of development of resistant strains in domiciliary and hospital acquired infections; (2) the frequency and seriousness of side effects; and (3) teratogenicity.
These problems will only be resolved by the continuing use of the combination under careful observation and control. The evidence available so far does not suggest that it is any more toxic than many other commonly used antibacterial agents.
From the point of view of practical chemotherapeutics other problems remain to be solved, in particular the importance of initial sulphonamide resistance in infecting bacteria treated with the combination, and the part played by synergic activity in controlling and eradicating infections. Until these problems are resolved by clinicomicrobiological studies the correct laboratory control of therapy with the combination will remain partly conjectural.
Finally, it would seem that the administration of a fixed ratio of the two drugs is not ideal for treating all infections. For 
